Abstract: In general, in one aspect, embodiments relate to a bulk dry cement that includes a dry blend of, a cement, a solid particle, and a solid resin accelerator, where the solid resin accelerator includes a liquid resin accelerator disposed and dried on the solid particle so as to be included in the bulk dry cement.

Abstract: A media processing engine selectively transcodes only a portion of the media clips to be included in a personalized media program and generates playback data that allows seamless playback of the personalized media program. The media processing engine analyzes initial playback data associated with the media program that indicates the media clips needed to generate the personalized media program. The media processing engine identifies one or more transitions between media clips in the personalized media program and determines specific segments of those media clips that are associated with the identified transition(s). The media processing engine performs transcoding operations with the determined segments of the media clips to generate one or more transition clips. The media processing engine then updates the initial playback data to indicate that the transition clip(s) should be played during the corresponding transition(s) between the associated media clips.

Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Abstract: A composition including a particulate, water, and a suspension aid comprising graphene, wherein the graphene comprises bioderived renewable graphene (BRG) and wherein the particulate is suspended in the composition. Methods of making and using the composition are also provided.

Abstract: A method may comprise operations for expanding a cement mixture with an alkali-silica reaction. The method may include positioning a cement mixture around a casing string downhole in a wellbore. The cement mixture may include a cement material and a silica material. The method may include curing the cement material to cause the cement material to contract. The silica material and alkali in the cement material may undergo an alkali-silica reaction to produce a gel that expands the cement mixture. The rate of expansion of the cement mixture from the gel may be equal to or greater than the rate of contraction of the cement mixture from curing.

Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: It is an object of the present invention to provide an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody-drug conjugate or the pharmaceutical composition, and the like. The present invention provides an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.

Abstract: The present invention provides a novel anti-DLL3 antibody-pyrrolodiazepine derivative and a novel anti-DLL3 anti-body-pyrrolodiazepine derivative conjugate using the same.

Abstract: A method of designing a cement slurry may include: (a) selecting a target permeability and a density requirement; (b) inputting the target permeability into a permeability model and generating a proposed cement composition using the permeability model, wherein the proposed cement composition comprises at least a cement and concentration thereof, and a water and concentration thereof such that a cement slurry formed from the proposed cement composition water meet the density requirement; (c) preparing the cement slurry based on the proposed cement composition; and (d) introducing the cement slurry into a wellbore and allowing the cement slurry to set to form a hardened cement.

Abstract: Embodiments relate to cementing operations and, in certain embodiments, to passivated cement accelerators and methods of using passivated cement accelerators in subterranean formations. An embodiment may comprise a method of cementing comprising: providing a cement composition comprising cement, water, and a passivated cement accelerator; and allowing the cement composition to set.

Abstract: A bulk dry cement may comprise a cement; a solid particle; and a liquid resin accelerator, wherein the liquid resin accelerator is disposed on a surface of the solid particle.

Abstract: Compositions for foamed treatment fluids are disclosed. The foamed treatment fluid may comprise a cement, a viscosifying agent, a thixotropic additive, a foaming surfactant, a gas, and water. The foaming surfactant may comprise a polyethylene glycol alkyl ether (C5-C10), sulfate ammonium salt.

Abstract: A method of cementing may include preparing a cement slurry by mixing at least water and a cement dry blend, wherein the cement dry blend comprises a cement and an activated pozzolan; and introducing the cement slurry into a wellbore penetrating a subterranean formation; and allowing the cement slurry to set to form a hardened mass.

Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of L1-CAM protein. The antibodies of the present technology are useful in methods for detecting and treating a L1-CAM-positive cancer in a subject in need thereof.

Abstract: The present invention provides a compound of formula (I) or a salt thereof: (Formula (I)) wherein X, L, V, R1; R2, R3 and R4, are as defined herein. The claimed compounds inhibit the enzyme 11-hydroxysteroid dehydrogenase type 2 (11-HSD2) and as a result are useful in the treatment of hyperkalemia by preventing cortisol from being oxidised to cortisone and thus allowing it to occupy the mineralocorticoid receptor, thus stimulating potassium excretion.

Abstract: A method of well treatment may include: providing a polymer; correlating performance of the polymer to a least one physical property of the polymer; and preparing a treatment fluid comprising the polymer.

Abstract: Preparing a cement slurry by mixing at least water and a cement dry blend, wherein the cement dry blend comprises a cement and an activated pozzolan; and introducing the cement slurry into a wellbore penetrating a subterranean formation; and allowing the cement slurry to set to form a hardened mass.

Abstract: Provided are methods, compositions, and systems embodying cement compositions and the synergistic effect of lost circulation materials (LCMs) and fluid loss control additives (FLCAs) thereupon for cementing subterranean zones. A method of subterranean well cementing, comprising providing a cement composition comprising a hydraulic cement, a first FLCA, a LCM, and water, wherein the first FLCA comprises a water-soluble polymer with repeating units comprising a 5- to 6-membered cyclic amide; introducing the cement composition into a wellbore penetrating a subterranean formation, wherein inclusion of the first FLCA and the LCM in the cement composition fluid reduces fluid loss into the subterranean formation, wherein the subterranean formation has fractures with a width of from about 1 micron to about 800 microns, and wherein the subterranean formation has a permeability of about 1 millidarcy to about 300 Darcy; and allowing the cement composition to set in the subterranean formation.

Abstract: A computer system generates a computer-guided personal care routine based at least in part on a digital model of a user's face. In an embodiment, a computer system generates the model based on one or more images or scans of the user's face, and generates a computer-guided personal care routine based on the model, environmental data (e.g., temperature data, humidity data, pollution data, UV radiation data), and user data. In an embodiment, a routine generated on this basis includes multiple steps to be carried out using a computer-controlled skin care device as well as user prompts related to execution of such steps that are configured to be presented in a user interface. In an embodiment, the computer-guided routine includes one or more operational settings (e.g., brush head speed, cleansing duration) for the computer-controlled skin care device that are automatically set at appropriate times according to the generated routine.

Abstract: The present invention provides a compound of formula (I) or a salt thereof: (I) wherein X, L, V, R1, R2, R3 and R4, are as defined herein. These compounds are inhibitors of 11-hydroxysteroid dehydrogenase type 2 (11-HSD-2) and are used to treat hyperkalemia.